Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 5, 2012, Pages 533-538

  Fuchs, Holger ^a   Runge, Frank ^a   Held, Heinz Dieter ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bile; Dipeptidyl peptidase 4 inhibitor; Linagliptin; P glycoprotein; Pharmacokinetics; Transport

Indexed keywords

GLYCOPROTEIN P; LINAGLIPTIN; ZOSUQUIDAR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; FECES; INTESTINE SECRETION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

ANIMALS; AREA UNDER CURVE; BILE; BILIARY TRACT; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DIABETES MELLITUS, TYPE 2; DIBENZOCYCLOHEPTENES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTESTINES; MALE; P-GLYCOPROTEIN; PURINES; QUINAZOLINES; QUINOLINES; RATS; RATS, WISTAR;

EID: 84857917241     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.11.018     Document Type: Article

References (16)

1. S. Blech, E. Ludwig-Schwellinger, E.U. Gräfe-Mody, B. Withopf, and K. Wagner The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab. Dispos. 38 2010 667 678
2. N. Bohannon Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice Postgrad. Med. 121 2009 40 45
3. C.F. Deacon, and J.J. Holst Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin. Invest. Drugs 19 2010 133 140
4. S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, and K.A. Dugi Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial Diab. Obes. Metab. 13 2011 258 267
5. H. Fuchs, R. Binder, and A. Greischel Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats Biopharm. Drug Dispos. 30 2009 229 240
6. H. Fuchs, J.P. Tillement, S. Urien, A. Greischel, and W. Roth Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans J. Pharm. Pharmacol. 61 2009 55 62
7. T. Heise, E.U. Graefe-Mody, S. Hüttner, A. Ring, D. Trommeshauser, and K.A. Dugi Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diab. Obes. Metab. 11 2009 786 794
8. S. Hüttner, E.U. Graefe-Mody, B. Withopf, A. Ring, and K.A. Dugi Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers J. Clin. Pharmacol. 48 2008 1171 1178
9. H. Kwon, R.A. Lionberger, and L.X. Yu Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates Mol. Pharm. 1 2004 455 465
10. S. Retlich, B. Withopf, A. Greischel, A. Staab, U. Jaehde, and H. Fuchs Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)-investigations in DPP-4 deficient and wildtype rats Biopharm. Drug Dispos. 30 2009 422 436
11. A.J. Scheen Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diab. Obes. Metab. 12 2010 648 658
12. J.J. Starling, R.L. Shepard, J. Cao, K.L. Law, B.H. Norman, J.S. Kroin, W.J. Ehlhardt, T.M. Baughman, M.A. Winter, M.G. Bell, C. Shih, J. Gruber, W.F. Elmquist, and A.H. Dantzig Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein Adv. Enzyme Regul. 37 1997 335 347 (Pubitemid 27371567)
13. R.H. Stephens, C.A. O'Neill, J. Bennett, M. Humphrey, B. Henry, M. Rowland, and G. Warhurst Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice Br. J. Pharmacol. 135 2002 2038 2046 (Pubitemid 34478317)
14. M.R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K.A. Dugi, and H.J. Woerle Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diab. Obes. Metab. 13 2011 65 74
15. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182 (Pubitemid 351439162)
16. U.S. Department of Health and Human Services Food and Drug Administration, 2001. Guidance for industry: bioanalytical method validation. Retrieved from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (accessed 12.10.2011).